# Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

> **NCT05539989** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **International Maternal Pediatric Adolescent AIDS Clinical Trials Group**

## Conditions studied

- Tuberculosis
- HIV Infections

## Interventions

- **BIOLOGICAL:** VPM1002 Vaccine
- **BIOLOGICAL:** BCG Vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05539989
- **Lead sponsor:** International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study is no longer moving forward due to the changing TB vaccine landscape.
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05539989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05539989, "Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05539989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*